Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort.
amyotrophic lateral sclerosis
body mass index
dysphagia
respiratory function
weight loss
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
15
09
2018
revised:
09
12
2018
accepted:
19
12
2018
pubmed:
12
1
2019
medline:
14
3
2020
entrez:
12
1
2019
Statut:
ppublish
Résumé
To assess the role of body mass index (BMI) and of the rate of weight loss as prognostic factors in amyotrophic lateral sclerosis (ALS) and to explore the clinical correlates of weight loss in the early phases of the disease. The study cohort included all ALS patients in Piemonte/Valle d'Aosta in the 2007-2011 period. Overall survival and the probability of death/tracheostomy at 18 months (logistic regression model) were calculated. Of the 712 patients, 620 (87.1%) were included in the study. Patients ' survival was related to the mean monthly percentage of weight loss at diagnosis (p<0.0001), but not to pre-morbid BMI or BMI at diagnosis. Spinal onset patients with dysphagia at diagnosis had a median survival similar to bulbar onset patients. About 20% of spinal onset patients without dysphagia at diagnosis had severe weight loss and initial respiratory impairment, and had a median survival time similar to bulbar onset patients. The rate of weight loss from onset to diagnosis was found to be a strong and independent prognostic factor in ALS. Weight loss was mainly due to the reduction of nutritional intake related to dysphagia, but a subgroup of spinal onset patients without dysphagia at diagnosis had a severe weight loss and an outcome similar to bulbar patients. According to our findings, we recommend that in clinical trials patients should be stratified according to the presence of dysphagia at the time of enrolment and not by site of onset of symptoms.
Identifiants
pubmed: 30630957
pii: jnnp-2018-319611
doi: 10.1136/jnnp-2018-319611
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
666-673Investigateurs
Stefania Cammarosano
(S)
Rosario Vasta
(R)
Maria Claudia Torrieri
(M)
Luca Solero
(L)
Marinella Clerico
(M)
Stefania De Mercanti
(S)
Alessandro Mauro
(A)
Luca Pradotto
(L)
Fabiola De Marchi
(F)
Luisa Sosso
(L)
Daniela Leotta
(D)
Lucia Appendino
(L)
Daniele Imperiale
(D)
Roberto Cavallo
(R)
Claudio Geda
(C)
Fabio Poglio
(F)
Paola Santimaria
(P)
Umberto Massazza
(U)
Antonio Villani
(A)
Roberto Conti
(R)
Luigi C Ruiz
(LC)
Mario Palermo
(M)
Franco Vergnano
(F)
Eugenia Rota
(E)
Maria Teresa Penza
(M)
Marco Aguggia
(M)
Piero Meineri
(P)
Paolo Ghiglione
(P)
Nicola Launaro
(N)
Giuseppe Astegiano
(G)
Giovanni Corso
(G)
Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: AC serves on a scientific advisory board for Mitsubishi Tanabe, Roche, and Cytokinetics.